Further advances in molecular screening and novel discoveries related to unique cancer molecular signatures, including the specific biomarkers of the cancer stem cells and the correlated action of receptors in cancer survival, such as the frequently reported CD44/EGFR axis, resulted in useful strategies for the development of dual-targeted NDDSs capable of attacking multiple targets for a more efficacious cancer treatment [2]. The gene discussed is EGFR; the disease is cancer.